NCT06414278 Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy
| NCT ID | NCT06414278 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Masonic Cancer Center, University of Minnesota |
| Condition | Hematopoietic and Lymphatic System Neoplasm |
| Study Type | OBSERVATIONAL |
| Enrollment | 38 participants |
| Start Date | 2024-02-08 |
| Primary Completion | 2027-07-21 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 38 participants in total. It began in 2024-02-08 with a primary completion date of 2027-07-21.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial evaluates the use of a tool kit, Stress, Affect, Language and Speech Analysis (SALSA), for early identification of cognitive side effects of immunotherapy compared to the standard of care assessment.
Eligibility Criteria
Inclusion Criteria: * \* ≥ 18 years of age at initiation of therapy * Planning to undergo inpatient CAR-T therapy for primary malignancy * Fluent in English (written or spoken) Exclusion Criteria: * \* Subjects with speech or hearing impediment that would make them unable to be assessed with SALSA * Subjects with diagnosed cognitive impairment prior to CAR-T therapy * Unwilling or unable to sign voluntary written consent
Contact & Investigator
Veronika Bachanova
PRINCIPAL INVESTIGATOR
Masonic Cancer Center, University of Minnesota
Frequently Asked Questions
Who can join the NCT06414278 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hematopoietic and Lymphatic System Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06414278 currently recruiting?
Yes, NCT06414278 is actively recruiting participants. Visit ClinicalTrials.gov or contact Masonic Cancer Center, University of Minnesota to inquire about joining.
Where is the NCT06414278 trial being conducted?
This trial is being conducted at Minneapolis, United States.
Who is sponsoring the NCT06414278 clinical trial?
NCT06414278 is sponsored by Masonic Cancer Center, University of Minnesota. The principal investigator is Veronika Bachanova at Masonic Cancer Center, University of Minnesota. The trial plans to enroll 38 participants.